Cellectis S.A. (CLLS)
NASDAQ: CLLS · IEX Real-Time Price · USD
2.900
+0.330 (12.84%)
May 2, 2024, 2:15 PM EDT - Market open

Cellectis Revenue

In the year 2023, Cellectis had annual revenue of $9.19M, a decrease of -64.26%. Revenue in the quarter ending December 31, 2023 was $1.99M, a -88.51% decrease year-over-year.

Revenue (ttm)
$9.19M
Revenue Growth
-64.26%
P/S Ratio
21.39
Revenue / Employee
$39,797
Employees
231
Market Cap
205.44M USD

Revenue Chart

* The company reports in EUR currency but revenue data is shown in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20239.19M-16.53M-64.26%
Dec 31, 202225.73M-12.87M-33.35%
Dec 31, 202138.60M-20.97M-35.20%
Dec 31, 202059.56M36.57M159.09%
Dec 31, 201922.99M1.56M7.27%
Dec 31, 201821.43M-12.28M-36.43%
Dec 31, 201733.72M-22.73M-40.27%
Dec 31, 201656.44M-6.12M-9.78%
Dec 31, 201562.57M31.43M100.95%
Dec 31, 201431.14M16.16M107.90%
Dec 31, 201314.98M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Rigel Pharmaceuticals 116.88M
OptimizeRx 71.52M
Innate Pharma 68.49M
Semler Scientific 68.18M
908 Devices 50.23M
MediWound 18.69M
Profound Medical 5.41M
Revenue Rankings